Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Clinical Trials Hanyan Yang

Advertisements

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

How to Participate in Research Eric Kleerup, M.D. & Donald Tashkin, M.D. David Geffen School of Medicine at UCLA Los Angeles, California.

PTP 661 EVIDENCE ABOUT INTERVENTIONS CRITICALLY APPRAISE THE QUALITY AND APPLICABILITY OF AN INTERVENTION RESEARCH STUDY Min Huang, PT, PhD, NCS.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

1 Seminar 6: Applied Epidemiology Chapters 8-10 Kaplan University School of Health Sciences.

Design of Clinical Trials

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

بسم الله الرحمن الرحیم.

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 The genomic nephrology workflow: genetic diagnosis and clinical application Figure 1 |The genomic nephrology workflow: genetic diagnosis and clinical.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 3 Proportion of patients for whom NEDA

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Milestones in paediatric acute kidney injury (AKI) research

Figure 1 Acute kidney injury and chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Figure 4 Model of changes in the serum levels

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Figure 3 Biologics that attenuate effector responses in the kidney

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The complement drug development pipeline

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2015.206 Figure 1 Design of a multicentre randomized controlled trial in rodents Figure 1 | Design of a multicentre randomized controlled trial in rodents. To improve the applicability of findings from interventional studies in rodents to randomized controlled trials in humans, robust clinical trial design must be adapted for rodent studies. Animals that fulfil predefined inclusion and exclusion criteria should be centrally randomized to receive different treatments that are administered in a blinded manner. Blinded evaluation of samples shipped from multiple centres to a core facility generates a high threshold for therapeutic effects and avoids investigator bias. A drug with proven efficacy under these rigorous conditions might be more likely to produce similar outcomes in a similarly designed trial in humans. Anders, H.-J. et al. (2016) Hurdles to the introduction of new therapies for immune-mediated kidney diseases Nat. Rev. Nephrol. doi:10.1038/nrneph.2015.206